Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of ixabepilone selected by DRP in recurrent or metastatic breast cancer
NL-OMON53513Phase 2Completed
- Sponsor
- Allarity Therapeutics
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ixabepilone in breast cancer, sponsored by Allarity Therapeutics. Primary endpoint: Clinical Benefit Rate. Started Aug 2023; status: completed.
02
Drugs
ixabepilone
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON53513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53513.